Ausio header

 

AUS-131 and Patents

At Ausio, we are working to discover and develop products to improve the lives of the aging population. Our lead compound, AUS-131, is a first-in-class, nonsteroidal, nonhormonal, small molecule (S-equol) that has higher selectivity toward estrogen receptor β (ERβ) than to estrogen receptor α (ERα). Two Phase 1 studies have seen completed and published; AUS-131 was safe and well tolerated in humans. A Phase 2a trial in menopausal women with vasomotor symptoms (VMS) has recently been completed (169 patients). A second Phase 2a trial in men with benign prostatic hyperplasia (BPH) is on track to be completed in 2015.

 

Patents

Ausio has rapidly garnered a strong patent position for S-equol.

US 7,396,855; US 7,960,432; US 8,048,913

Issued July 8, 2008 (Expiry December 3, 2024)
Composition and Products Containing S-equol, and Methods for their Making

US 7,528,267; US 7,960,573; US 8,263,790; US 8,716,497

Issued May 5, 2009 (Expiry January 27, 2027)
Method for Enantioselective Hydrogenation of Chromenes

AUS 2006275587

Method for Enantioselective Hydrogenation of Chromenes

AUS 2002359220

Issued December 15, 2008 (Expiry July 24, 2023)
Compositions and Products Containing Enantiomeric Equol, and Methods for their Making

China 200680036577.1

Method for Enantioselective Hydrogenation of Chromenes

China ZL03822155.1

Issued May 26, 2010 (Expiry July 24, 2023)
Compositions and Products Containing Enantiomeric Equol, and Methods for their Making

Japan 5507081

Method for Enantioselective Hydrogenation of Chromenes

Japan, EU, and others Pending Office Action

 

Ausio License to Novagen patents US 6,649,648; US 6,455,032

 

 
   

Home Contact UsDirections